Palatin Technologies (PTN) Liabilities and Shareholders Equity (2011 - 2026)
Palatin Technologies' (PTN) quarterly Liabilities and Shareholders Equity came in at $13.2 million in Q1 2026, up 254.71% YoY from $3.7 million in Q1 2025, and down 26.23% on a QoQ basis from $17.9 million in Q4 2025.
Palatin Technologies (PTN) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $13.2 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 254.71% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.0 million (up 93.88% YoY) and the FY2025 annual result came in at $3.3 million, down 69.59% from the prior year.
- Liabilities and Shareholders Equity fell to $13.2 million in Q1 2026, from $17.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $43.8 million in Q1 2022 to a low of $3.3 million in Q2 2025.
- A 5-year average of $16.7 million and a median of $13.2 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity plunged 69.64% — and 2025, when it soared 315.95%.
- Tracing PTN's Liabilities and Shareholders Equity over 5 years: stood at $32.0 million in 2022, then slumped by 57.61% to $13.6 million in 2023, then tumbled by 68.2% to $4.3 million in 2024, then soared by 315.95% to $17.9 million in 2025, then slipped by 26.23% to $13.2 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $13.2 million (Q1 2026), $17.9 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | 13.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.23 Mn |
| Dec 31, 2025 | 17.93 Mn |
| Sep 30, 2025 | 8.61 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 4.31 Mn |
| Sep 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 10.74 Mn |
| Mar 31, 2024 | 11.41 Mn |
| Dec 31, 2023 | 13.55 Mn |
| Sep 30, 2023 | 11.25 Mn |
| Jun 30, 2023 | 17.94 Mn |
| Mar 31, 2023 | 25.61 Mn |
| Dec 31, 2022 | 31.98 Mn |
| Sep 30, 2022 | 27.64 Mn |
| Jun 30, 2022 | 36.07 Mn |
| Mar 31, 2022 | 43.82 Mn |
| Dec 31, 2021 | 52.99 Mn |
| Sep 30, 2021 | 59.73 Mn |
| Jun 30, 2021 | 67.30 Mn |